Home › Compare › ENJPY vs ABBV
ENJPY yields 2.74% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ENJPY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENJPY + ABBV for your $10,000?
en-japan inc. provides online recruitment, recruiting and staffing, employee training, and HR consulting and aptitude test services in Japan and internationally. The company operates job information sites, including en TENSHOKU for various recruitment and career change support services; en TENSHOKU WOMAN, a career-change support services for women; AMBI, a career change site designed for young people; MIDDLE NO TENSHOKU, a recruitment website; en HAKEN, a job-search site for temporary employment; en BAITO, a recruitment website for part-time and casual job information; en WOMEN WORK, a recruitment site for women professionals; and ONNA NO KYUJIN MART, a centralized recruitment site for female professionals. It also provides recruiting services, such as en AGENTS that offers professional and specialized support services; en Lighthouse, a word-of-mouth site; CAREER HACK, a career information site for professionals in web and IT industries; and SMART GYOKAI MAP, an industry research site that explains various companies and trends in specific industries. In addition, the company operates en JINJI NO MIKATA, a recruitment support services for HR professionals; en COLLEGE for employee education services; engage, a website for recruitment support tool; HR OnBoard, an employee retention risk identification tool; and 3E TEST for assessing the talent pool, as well as provides evaluation and education consulting services. The company was founded in 2000 and is based in Tokyo, Japan.
Full ENJPY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.